CTLA4 and neoplasm: DMAbs can also conceptually simplify combination therapies, allowing administration of anti-CTLA4 and anti-PD-1 combinations with a single injection or providing simplified immune combinations for study such as cancer vaccines [5, 12] or DMAbs targeting other tumor targets [4].